Improved Skeletal Dynamics in Adults Treated With Palopegteriparatide for Hypoparathyroidism: 52-Week Analysis of Phase 3 PaTHway Trial

Introduction: Evaluate the temporal changes in and relationship between skeletal endpoints in response to palopegteriparatide (TransCon PTH), a prodrug with sustained release of PTH(1-34), in individuals with chronic hypoparathyroidism.